This long into a pandemic, you would have thought that Clinigen might have seen Covid-related disruption to cancer treatments and clinical trials coming. But on June 9 the AIM-listed provider of medicines issued a shock profit warning after Covid kept cancer patients away from hospitals. The announcement sent the shares down by 25 per cent.
Historically, Clinigen’s communications with investors could have been better. In May last year, it announced that JP Morgan would become its nominated adviser and joint broker — replacing Numis. Seven months later, JP Morgan was out and Numis back in.
Since listing on AIM in 2012, Clinigen has grown via acquisitions, including of Idis in 2015 for £225 million and Link Healthcare in the same year for £100 million. In